Sarbari Ghosh, PhD
Cell and Gene Therapy/CAR-T/Lentiviral vectors
Mob: +91-9831084247
Electronic City Phase-I, Bengaluru-560100
Email: sarbarionline@gmail.com
LinkedIn Profile: https://www.linkedin.com/in/sarbari-ghosh-307b7286/

Scientist with ability to lead and contribute to research projects with 10+ years of professional and academic experience in Cell and Gene Therapy (CGT), Cancer Immunotherapy and T cell Immunology. Hands on experience with platform optimization and process development for India's first (*NexCAR19 by ImmunoACT*) and second (*Qartemi by Immuneel Therapeutics Pvt Ltd.*) commercially approved CAR-T products.

PROFESSIONAL EXPERIENCE

November 2024- Present: Specialist, Manufacturing Science & Technology (MSAT) CART, Dr Reddys Laboratories (DRL), Bengaluru, Karnataka.

- Leading the Process development/MSAT team of 3 members by developing and refining manufacturing procedures.
- Performing risk analyses/FMEA model analysis to identify potential gaps/improvements within current manufacturing processes and implementing mitigation strategies.
- Actively involved in preparation of URS, QRA, DQ checklist, Commissioning, IOQ protocols and QMS elements for lab and equipment qualification in a Greenfield project.
- Key role in Technology Transfer from Knowledge partner and execution of PPQ runs at DRL site.

August 2021- November 2024: Scientist, Process Development (PD), Immuneel Therapeutics Pvt Ltd, Bengaluru, Karnataka.

- Contributed to developing India's second CAR-T cell drug product, Qartemi for B-NHL.
- Optimized critical parameters for scale up and scale out LVV production models.
- Developed suspension HEK293T cell lines by serum depletion of adherent cells.
- Worked end to end to optimize semi-automated CAR-T platform for reduction of COGS.
- Experience in documentation for QTPP, process development report, tech transfer, BMRs/BPRs, SOPs, EOPs.
- Managed training and day to day activities for research assistants and interns.
- Well versed with generating and applying new research protocols and technologies.

October 2020- July 2021: Senior Variant Analyst, Pieriandx India Pvt. Ltd, Pune, Maharashtra.

- Worked on curating, interpreting clinical data for pathological laboratory-based clients (USA based).
- Drafted genetic mutation variant analysis reports within a TAT of 48 hours.

January 2018-October 2020: Post-doctoral fellow, IIT-Bombay, Mumbai, Maharashtra.

- Contributed to developing India's first CAR-T cell drug product, NexCAR19 for B-ALL.
- Worked on the development of indigenous chimeric antigen receptor (CAR) T cell therapy platform.
- Developed pre-clinical murine model for in-vivo efficacy studies for *NexCAR19*.

RELEVANT TECHNICAL SKILLS

- Cell culture, Transfection, Transduction in mammalian cells
- Lentivirus production in multilayer flasks (12/36 layer) and shake flasks (1-5 Litres)
- Cell line adaptation for viral vector production
- Transduction and MOI titration in primary cells like T cells
- CAR-T cell generation & expansion in culture flasks, GPBs, GREX bioreactors, CliniMACS Prodigy platform
- In-vivo drug efficacy studies in murine tumor models of sarcoma, B16 melanoma.
- In-vivo bioluminescence imaging for tumor growth monitoring in NOD-SCID/NSG murine tumor models
- Multi-color Flow Cytometry, panel designing, T cell immunophenotyping
- In- vitro potency assays (both flow and non-flow based)

EDUCATION

- Ph.D in Microbiology, *University of Calcutta (2011-2017)*
- M.Sc in Biotechnology, *KIIT University (2008-2010, Gold medalist)*
- B.Sc in Microbiology, *University of Calcutta (2005-2008)*

AWARDS & ACHIEVEMENTS

- INSPIRE Fellowship from DST, Govt of India; 2011
- CSIR-UGC National Eligibility Test (NET) for LS; 2010
- Chancellor's Gold medal, KIIT University; 2010
- POSCO Asia Fellowship, KIIT University; 2009
- Lifetime member of Indian Immunology Society (IIS) & Indian Association of Cancer Research (IACR)

PUBLICATIONS, CONFERENCES ATTENDED & GOVERNMENT GRANTS

- 19 peer reviewed publications & 2 review articles in international journals.]
- Conferences attended 9 and presented in 6
- Grant writing: ICMR project on Role of TAMs in tumorigenesis, DBT-BIRAC proposal on GD2 specific CAR-T cells